(MDPI, 2023) Cabello Olmo, Miriam; Oneca Agurruza, María; Urtasun Alonso, Raquel; Pajares Villandiego, María Josefa; Goñi Irigoyen, Saioa; Riezu Boj, José I.; Milagro Yoldi, F. I.; Ayo, Josune; Encío Martínez, Ignacio; Barajas Vélez, Miguel Ángel; Araña Ciordia, Miriam; Ciencias de la Salud; Osasun Zientziak
Type 2 diabetes (T2D) is a complex metabolic disease, which involves maintained hyperglycemia, mainly due to the development of an insulin resistance process. Metformin administration
is the most prescribed treatment for diabetic patients. In a previously published study, we demonstrated that Pediococcus acidilactici pA1c® (pA1c) protects from insulin resistance and body weight
gain in HFD-induced diabetic mice. The present work aimed to evaluate the possible beneficial
impact of a 16-week administration of pA1c, metformin, or the combination of pA1c and metformin
in a T2D HFD-induced mice model. We found that the simultaneous administration of both products attenuated hyperglycemia, increased high-intensity insulin-positive areas in the pancreas and
HOMA-β, decreased HOMA-IR and also provided more beneficial effects than metformin treatment (regarding HOMA-IR, serum C-peptide level, liver steatosis or hepatic Fasn expression), and
pA1c treatment (regarding body weight or hepatic G6pase expression). The three treatments had a
significant impact on fecal microbiota and led to differential composition of commensal bacterial
populations. In conclusion, our findings suggest that P. acidilactici pA1c® administration improved
metformin beneficial effects as a T2D treatment, and it would be a valuable therapeutic strategy to
treat T2D.
